RVL PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.00% |
|
0.00% | 0.00% |
| Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
| Mar. 21 | North American Morning Briefing : Investors -2- | DJ |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Capitalization 1 | 407 | 363 | 257.9 | 89.95 | 111.1 |
| Enterprise Value (EV) 1 | 605 | 540.4 | 366.3 | 97.15 | 124 |
| P/E ratio | -3.2 x | -1.35 x | -3.14 x | -1.12 x | -1.95 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 1.54 x | 1.51 x | 1.45 x | 5.14 x | 2.23 x |
| EV / Revenue | 2.29 x | 2.25 x | 2.06 x | 5.55 x | 2.49 x |
| EV / EBITDA | 7.82 x | 9.99 x | 17.4 x | -1.41 x | -3.13 x |
| EV / FCF | 13.8 x | 14.9 x | 24.3 x | -4.15 x | -9.78 x |
| FCF Yield | 7.25% | 6.71% | 4.12% | -24.1% | -10.2% |
| Price to Book | 1.05 x | 3.16 x | 2.75 x | 1.17 x | 2.17 x |
| Nbr of stocks (in thousands) | 52,519 | 51,926 | 62,586 | 83,290 | 99,154 |
| Reference price 2 | 7.750 | 6.990 | 4.120 | 1.080 | 1.120 |
| Announcement Date | 3/28/19 | 3/19/20 | 3/30/21 | 3/30/22 | 3/20/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 245.7 | 263.7 | 240 | 177.9 | 17.5 | 49.72 |
| EBITDA 1 | 66.28 | 77.36 | 54.1 | 21.02 | -69.14 | -39.6 |
| EBIT 1 | 30.68 | 5.683 | 3.052 | 1.747 | -77.31 | -39.98 |
| Operating Margin | 12.49% | 2.16% | 1.27% | 0.98% | -441.75% | -80.41% |
| Earnings before Tax (EBT) 1 | -85.64 | -118.7 | -298 | -84.29 | -82.53 | -51.71 |
| Net income 1 | -45.15 | -109.4 | -270.9 | -79.59 | -64.92 | -51.69 |
| Net margin | -18.37% | -41.48% | -112.86% | -44.74% | -370.95% | -103.96% |
| EPS 2 | -45.14 | -2.420 | -5.173 | -1.312 | -0.9639 | -0.5757 |
| Free Cash Flow 1 | 32.75 | 43.86 | 36.25 | 15.09 | -23.41 | -12.68 |
| FCF margin | 13.33% | 16.63% | 15.1% | 8.48% | -133.74% | -25.5% |
| FCF Conversion (EBITDA) | 49.42% | 56.7% | 67.01% | 71.79% | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/9/18 | 3/28/19 | 3/19/20 | 3/30/21 | 3/30/22 | 3/20/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23.88 | 34.8 | 2.196 | 2.86 | 21.44 | 8.448 | 10.02 | 9.807 | 8.832 | 8.258 |
| EBITDA | -5.777 | -8.35 | -20.32 | -15.23 | -18.9 | -11.75 | -10.91 | -9.32 | -8.655 | - |
| EBIT 1 | -6.206 | -12.3 | -25.17 | -23.06 | -5.396 | -15.12 | -13.92 | -24.55 | -10.29 | -8.121 |
| Operating Margin | -25.99% | -35.34% | -1,146.08% | -806.22% | -25.16% | -179.02% | -138.91% | -250.31% | -116.52% | -98.34% |
| Earnings before Tax (EBT) 1 | -9.079 | -17.42 | -26.02 | -19.78 | -6.896 | -11.83 | -14.38 | -18.6 | -11.55 | -24 |
| Net income 1 | -9.612 | -17.73 | -17.86 | -19.72 | -6.821 | -12.11 | -14.45 | -18.32 | -11.61 | -23.89 |
| Net margin | -40.25% | -50.94% | -813.25% | -689.58% | -31.81% | -143.3% | -144.14% | -186.8% | -131.48% | -289.28% |
| EPS 2 | -0.1500 | -0.2800 | -0.2800 | -0.2400 | -0.0800 | -0.1400 | -0.1600 | -0.1900 | -0.1200 | -0.2400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/13/21 | 8/16/21 | 11/15/21 | 3/30/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/20/23 | 5/11/23 | 8/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 286 | 198 | 177 | 108 | 7.2 | 12.9 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 4.314 x | 2.559 x | 3.28 x | 5.156 x | -0.1042 x | -0.3269 x |
| Free Cash Flow 1 | 32.8 | 43.9 | 36.3 | 15.1 | -23.4 | -12.7 |
| ROE (net income / shareholders' equity) | -10.5% | -26.6% | -109% | -76.3% | -97.1% | -80.9% |
| ROA (Net income/ Total Assets) | 2.09% | 0.41% | 0.3% | 0.26% | -18.7% | -18.3% |
| Assets 1 | -2,166 | -26,418 | -89,406 | -30,412 | 346.4 | 282.6 |
| Book Value Per Share 2 | 405.0 | 7.350 | 2.210 | 1.500 | 0.9200 | 0.5200 |
| Cash Flow per Share 2 | 34.70 | 1.350 | 1.850 | 1.820 | 0.4900 | 0.4500 |
| Capex 1 | 19.4 | 4.14 | 3.96 | 2.92 | 1.78 | 0.75 |
| Capex / Sales | 7.89% | 1.57% | 1.65% | 1.64% | 10.18% | 1.51% |
| Announcement Date | 5/9/18 | 3/28/19 | 3/19/20 | 3/30/21 | 3/30/22 | 3/20/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 111 | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- RVLPQ Stock
- Financials RVL Pharmaceuticals plc
